top of page
Search

DECHRA PHARMACEUTICALS' PET PROJECTS ARE PAYING OFF

  • Writer: christine
    christine
  • Jul 10, 2019
  • 1 min read

WE LOVE DECHRA

Another of our shares highlighted in The Times this morning.

Dechra is a multibillion-pound pet medicines business and is in rude health after gobbling up rivals and delivering strong annual trading.

The company said that it had increased group revenue by about 17% in the year to the end of June. European pharmaceuticals revenue growth was about 18% and in North America it was about 15%


Dechra has been transformed into a near £3 billion UK veterinary pharmaceuticals company, boosted by a series of deals, including last year's £298 million acquisitions of AST and Le Vet, the European vet pharma companies.


Up almost 3% today with hopefully more to come.

Well done China Dolls.


 
 
 

Recent Posts

See All
SPRING CLEANING

CERES POWER: SOLD In October 2024, Goldman Sachs cut its recommendation for Ceres Power shares to neutral due to a correction in the...

 
 
 

Comentários


bottom of page